Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;28(7):1557-60.
doi: 10.1038/leu.2014.72. Epub 2014 Feb 17.

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

X Niu  1 , G Wang  2 , Y Wang  3 , J T Caldwell  4 , H Edwards  5 , C Xie  6 , J W Taub  7 , C Li  3 , H Lin  8 , Y Ge  6
Affiliations

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

X Niu et al. Leukemia. 2014 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Panel A: Cell lines were treated with ABT-199 for 24 h. Apoptotic events (Annexin V+) were determined by Annexin V/PI staining and flow cytometry analyses. Panel B: AML cell lines were cultured for 72 h in the presence of variable concentrations of ABT-199 and viable cell numbers were determined using MTT reagent and a microplate reader. IC50 values were calculated as drug concentration necessary to inhibit 50% proliferation compared to untreated control cells. The horizontal lines indicate the median. Panel C: Freshly isolated AML patient samples were purified by standard Ficoll-Hypaque density centrifugation. AML patient samples #10 and #12 were treated with ABT-199 for 24 h and apoptotic events were determined by Annexin V/PI staining and flow cytometry analyses. Panel D: Ex vivo ABT-199 sensitivity was determined using MTT assays. The horizontal lines indicate median ABT-199 IC50s in each group of AML patient samples (Panel D). Panel E: Total RNAs were isolated and gene transcript levels were determined by Real-time RT-PCR. Transcript levels were normalized to GAPDH and relative expression levels were calculated using the comparative Ct method (comparing all samples to the CMS cell line expression levels). The Bcl-2/Mcl-1 ratios for the AML cell line and patient samples were graphed against the ABT-199 IC50. Panel F: MV4-11 cells were infected with Precision LentiORF Mcl-1, Bcl-xL, or red fluorescent protein control (designated MV4-11/Mcl-1, MV4-11/Bcl-xL, and MV4-11/RFP respectively) lentivirus overnight, washed, and incubated for 48 h prior to adding selection drug (blasticidin) to the culture medium. Whole cell lysates were subjected to Western blotting and probed with anti-Bcl-xL, -Mcl-1, -Bcl-2 or –β-actin antibody. Panel G: MV4-11/Mcl-1, MV4-11/Bcl-xL, and MV4-11/RFP were treated with ABT-199 for 24 h and apoptotic events were determined by Annexin V/PI staining and flow cytometry analyses. The p values were calculated using the Mann-Whitney U test. The relationship between the Bcl-2 family transcript levels/ratios and ABT-199 sensitivity were determined by the nonparametric Spearman rank correlation coefficient.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63 (1):11–30. - PubMed
    1. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The lancet oncology. 2010;11(6):543–52. - PMC - PubMed
    1. Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. American journal of hematology. 2004;75(1):22–33. - PubMed
    1. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11(12):2075–8. - PubMed
    1. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(25):3127–35. - PMC - PubMed

Publication types

MeSH terms

Substances